ACTRN12614000731695招募中1 期
A Phase I Study to Evaluate the Safety and Efficacy of Mesenchymal Stromal Cells (MSC) for Treating Chronic Obstructive Pulmonary Disease (COPD)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 60 Years 至 70 Years（—）
- 性别
- All
入选标准
- •Moderate to severe COPD (GOLD 2-3)
排除标准
- •Inability to give consent
- •Cardiac failure
- •Renal failure
- •Liver failure
- •Active cancer
研究者
相似试验
已完成
1 期
DCB-DM101 in Participants with Type 2 Diabetes MellitusType 2 Diabetes MellitusACTRN12618001140246VitNovo Australia Pty Ltd24
进行中（未招募）
1 期
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)Small Cell Lung CancerJPRN-jRCT2031220086Tagashira Shuzo50
招募中
1 期
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapyExtensive Stage Small Cell Lung CancerJPRN-jRCT2031220277Tagashira Shuzo340
尚未招募
不适用
A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancerlung cancerNL-OMON53561Amgen4
招募中
1 期
Safety and Efficacy of MagSense Human Epidermal Growth Factor Receptor 2 (HER2) Test Reagent in Breast Cancer Lymph Node Magnetic Reasonance Imaging (MRI) and Magnetic Relaxometry (MRX).Cancer - BreastBreast CancerACTRN12621000126819Imagion Biosystems, Ltd30